NCT06484673View on ClinicalTrials.gov

Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 21, 2024

Primary Completion Date

May 22, 2024

Study Completion Date

May 27, 2024

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Bosentan Dispersible Tablets

1 tablet of 32 mg Bosentan

DRUG

Tracleer Tablet for Oral Suspension

1 tablet of 32 mg Bosentan

Trial Locations (1)

Unknown

ACDIMA Biocenter, Amman

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT06484673 - Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets | Biotech Hunter | Biotech Hunter